Lv41
610 积分 2025-08-25 加入
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
6小时前
待确认
A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor
7小时前
待确认
Preclinical discovery and clinical development of glofitamab in relapsed/ refractory large B-cell lymphomas
14天前
已完结
Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China
24天前
已完结
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial
28天前
已完结
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
28天前
已完结
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
1个月前
已完结
Glofitamab with Polatuzumab Vedotin in Refractory Burkitt’s Lymphoma
1个月前
已完结
Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001
1个月前
已完结
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
1个月前
已完结
皖公网安备34019202002308
